FindTrial
Sign In

ibritumomab tiuxetan

DRUG8 trials

Sponsors

SCRI Development Innovations, LLC, GlaxoSmithKline, Northwestern University, Swiss Cancer Institute, University of Miami

Conditions

LymphomaLymphoma, FollicularLymphoma, Large-Cell, FollicularLymphoma, Non-HodgkinLymphoma, Small Cleaved-Cell, FollicularMarginal Zone LymphomaNon-Hodgkin's LymphomaNon-Hodgkins Lymphoma

Phase 1

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
TerminatedNCT00372905
Northwestern UniversityLymphoma
Start: 2007-07-24End: 2013-07-08Updated: 2019-09-04
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
CompletedNCT00392691
Swiss Cancer InstituteLymphoma
Start: 2006-10-31End: 2013-05-31Updated: 2019-05-15

Phase 2

Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
CompletedNCT00193440
SCRI Development Innovations, LLCNon-Hodgkins Lymphoma
Start: 2002-04-30End: 2009-01-31Target: 40Updated: 2010-12-30
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
CompletedNCT00453102
University of MiamiMarginal Zone Lymphoma
Start: 2006-02-28End: 2015-02-28Updated: 2016-01-01
ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
CompletedNCT00662948
PETHEMA FoundationLymphoma
Start: 2008-12-31End: 2017-10-30Updated: 2020-04-28
Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
NCT01811368
Joseph TuscanoRefractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma
Start: 2013-03-12End: 2023-12-31Target: 20Updated: 2022-11-30

Phase 3

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
WithdrawnNCT00319332
GlaxoSmithKlineLymphoma, Follicular, Lymphoma, Large-Cell, Follicular, Lymphoma, Non-Hodgkin +1
Start: 2005-09-30End: 2021-02-28Updated: 2015-04-17
Zevalin-beam for Aggressive Lymphoma
CompletedNCT00491491
Sheba Medical CenterNon-Hodgkin's Lymphoma
Start: 2007-06-30End: 2015-02-28Updated: 2020-08-31

Related Papers

A randomized phase II study comparing consolidation with a single dose of <sup>90</sup>Y ibritumomab tiuxetan <i>vs.</i> maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Leukemia & lymphoma/Leukemia and lymphoma2021-08-3011 citations
Phase II study of<sup>90</sup>Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma
Leukemia & lymphoma/Leukemia and lymphoma2014-10-1527 citations
A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization
Blood2013-11-1526 citations